Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M118,003Revenue (TTM) $M16,910Net Margin (%)9.3Altman Z-Score6.4
Enterprise Value $M120,560EPS (TTM) $0.9Operating Margin %11.1Piotroski F-Score4
P/E(ttm)76.0Beneish M-Score-1.9Pre-tax Margin (%)13.5Higher ROA y-yN
Price/Book8.310-y EBITDA Growth Rate %-4.0Quick Ratio1.3Cash flow > EarningsN
Price/Sales7.15-y EBITDA Growth Rate %-19.0Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-19.9ROA % (ttm)4.9Higher Current Ratio y-yN
Dividend Yield %2.1PEG--ROE % (ttm)10.6Less Shares Outstanding y-yN
Payout Ratio %160Shares Outstanding M1,669ROIC % (ttm)5.7Gross Margin Increase y-yN

Gurus Latest Trades with BMY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYVanguard Health Care Fund 2016-03-31 Add0.21%$58.87 - $68.79
($63.1)
$ 70.6912%Add 3.29%47,754,809
BMYT Rowe Price Equity Income Fund 2016-03-31 Reduce-0.15%$58.87 - $68.79
($63.1)
$ 70.6912%Reduce -10.82%4,031,100
BMYKen Fisher 2016-03-31 Add0.07%$58.87 - $68.79
($63.1)
$ 70.6912%Add 371.85%636,060
BMYRon Baron 2016-03-31 Buy 0.04%$58.87 - $68.79
($63.1)
$ 70.6912%New holding112,848
BMYMario Gabelli 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 70.6912%Add 2.29%654,005
BMYKahn Brothers 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 70.6912%Add 1.90%28,583
BMYRonald Muhlenkamp 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 70.6912%Add 0.21%212,200
BMYDodge & Cox 2016-03-31 Reduce$58.87 - $68.79
($63.1)
$ 70.6912%Reduce -5.16%73,458
BMYRuane Cunniff 2016-03-31 Sold Out $58.87 - $68.79
($63.1)
$ 70.6912%Sold Out0
BMYT Rowe Price Equity Income Fund 2015-12-31 Reduce-0.26%$59.88 - $70.71
($66.18)
$ 70.697%Reduce -18.01%4,520,000
BMYVanguard Health Care Fund 2015-12-31 Add0.12%$59.88 - $70.71
($66.25)
$ 70.697%Add 1.95%46,232,449
BMYTom Gayner 2015-12-31 Buy 0.02%$59.88 - $70.71
($66.25)
$ 70.697%New holding10,000
BMYKen Fisher 2015-12-31 Add0.01%$59.88 - $70.71
($66.18)
$ 70.697%Add 120.33%134,800
BMYJoel Greenblatt 2015-12-31 Sold Out -0.01%$59.88 - $70.71
($66.25)
$ 70.697%Sold Out0
BMYGeorge Soros 2015-12-31 Sold Out -0.01%$59.88 - $70.71
($66.25)
$ 70.697%Sold Out0
BMYKahn Brothers 2015-12-31 Reduce-0.01%$59.88 - $70.71
($66.25)
$ 70.697%Reduce -2.60%28,050
BMYMario Gabelli 2015-12-31 Reduce$59.88 - $70.71
($66.25)
$ 70.697%Reduce -1.85%639,355
BMYDodge & Cox 2015-12-31 Reduce$59.88 - $70.71
($66.25)
$ 70.697%Reduce -3.09%77,458
BMYFirst Eagle Investment 2015-12-31 Reduce$59.88 - $70.71
($66.25)
$ 70.697%Reduce -2.87%12,943
BMYVanguard Health Care Fund 2015-09-30 Add0.21%$57.3 - $70.06
($63.44)
$ 70.6911%Add 3.72%45,346,149
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bancroft Charles AEVP & CFO 2016-05-20Sell30,201$70.79-0.16view
Caldarella Joseph CSVP & Controller 2016-05-16Sell3,519$72.47-2.47view
LEUNG SANDRAEVP, General Counsel 2016-05-06Sell72,544$70.390.41view
ANDREOTTI LAMBERTODirector 2016-05-05Sell23,200$70.540.2view
Caforio GiovanniCEO 2016-05-03Sell34,594$71.31-0.88view
Nielsen AnneChief Compliance & Ethics Off 2016-05-02Sell28,451$71.88-1.67view
von Autenried PaulSVP, Enterp. Services & CIO 2016-05-02Sell37,258$71.93-1.74view
ANDREOTTI LAMBERTODirector 2016-05-02Sell234,720$71.88-1.67view
Schmukler Louis SPres., Global Mfg. & Supply 2016-05-02Sell22,218$71.95-1.77view
ANDREOTTI LAMBERTODirector 2016-04-05Sell23,200$65.97.25view

Press Releases about BMY :

Quarterly/Annual Reports about BMY:

News about BMY:

Articles On GuruFocus.com
Baron Funds Comments on Bristol-Myers Squibb May 23 2016 
Baron Funds Comments on Bristol-Myers Squibb Company May 06 2016 
John Burbank Raises Stake in Microsoft Mar 02 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
Designing the Appropriate Common Stock Retirement Portfolio: Stock Selection Options Part 1 Sep 14 2015 
Weekly Insider Sells Highlight: IMS, NOW, BMY, EA Aug 11 2015 
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 

More From Other Websites
4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends May 25 2016
Bloomsbury Publishing Plc :BMY-GB: Earnings Analysis: For the six months ended February 29, 2016 :... May 25 2016
Bloomsbury Publishing Plc :BMY-GB: Earnings Analysis: 2016 By the Numbers : May 25, 2016 May 25 2016
[$$] Bristol-Myers Could Grow EPS 16% Per Year May 24 2016
Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained... May 23 2016
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights May 23 2016
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights May 23 2016
Coverage initiated on Bristol-Myers by Hilliard Lyons May 23 2016
FDA staff question dosing of Sanofi combination diabetes drug May 23 2016
FDA staff question dosing of Sanofi combination diabetes drug May 23 2016
A Rudderless Market May 23 2016
Looking for a Top Momentum Stock? 3 Reasons Why Bristol-Myers (BMY) is a Great Choice May 20 2016
Inovalon And Bristol-Myers Squibb Strike Deal To Focus On Real World Outcomes & Value-Based... May 19 2016
Inovalon Announces Agreement with Bristol-Myers Squibb to Focus on Real World Outcomes & Value-Based... May 19 2016
Bristol-Myers Reports Two-Year Overall Survival Opdivo Data May 19 2016
Inovalon Announces Agreement with Bristol-Myers Squibb to Focus on Real World Outcomes & Value-Based... May 19 2016
New Hope for Melanoma Patients May 18 2016
Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained... May 18 2016
Merck, Bristol drugs show longer survival for deadly cancers May 18 2016
The Highest-Earning Hedge Fund Manager in 2015 Reveals His Top Stock Picks for Q2 May 18 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)